More Science Backs Green Teas Ability to Block Prostate Cancer
Excessive production of the COX-2 enzyme, an enzyme involved in inflammation, is involved in
many disease states including cancer. The ability to inhibit COX-2 is a promising target for
cancer prevention and even cancer therapy. Recently developed COX-2 specific inhibitors have
shown considerable promise in the prevention of some forms of cancer, however their use is
limited due to severe toxic effects on healthy tissue cells.
Therefore there is a need for novel and nontoxic dietary ingredients with proven cancer
preventing effects through other pathways that inhibit COX-2 but not COX-1. Recent studies on
Green Tea and its major polyphenol EGCG have established its remarkable cancer preventive and
some cancer treatment effects. In this study researchers form the University of Wisconsin and
Case Western Reserve University show that EGCG inhibits COX-2 but not COX-1 in both androgen
dependent, and androgen independent human prostate cancer tissue. The study is published in the
February 10th 2005 issue of the International Journal of Cancer.
L-Carnitine may Prevent Liver Cancer in Hepatitis Patients
Carcinoma (cancer) of the liver is usually preceded by long-term liver inflammation. The
mitochondria is the part of the cell that creates energy. Dysfunction of the mitochondria,
and its subsequent generating of free radicals plays an important role in the creation of liver
cancer. These researchers have previously proven that L-Carnitine effectively protects
mitochondrial function in living animals.
In this study the researchers investigated whether long-term administration of L-Carnitine
could prevent liver cancer in rats typically used as a model of liver cancer development.
L-Carnitine significantly inhibited the formation of free radicals that cause mitochondrial
dysfunction and liver cell death. Markers of the formation of liver cancer were also significantly
inhibited. The study shows that mitochondrial injury plays an essential role in the formation of
liver cancer and that supplementation with L-Carnitine has excellent therapeutic potential in
patients with chronic hepatitis. The study is published in the February 20th, 2005 issue of the
International Journal of Cancer.